Lobbying Information
Subject Matters
- Economic Development
- Health
- Industry
- Intellectual Property
- International Trade
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.
- Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
Policies or Program
- Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
- Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- The government's Science and Technology Strategy potential policies and programs pertaining to the biopharmaceutical industry
Regulation
- Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business
- Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
- Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Federal Economic Development Agency for Southern Ontario (FedDev)
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Great Lakes Pilotage Authority
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Pharmaceutical manufacturer, research and development, commercial operations.
Responsible officer name and position during the period of this registration
Kenneth L Custer,
President and General Manager
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
P. O. Box 73, Exchange Tower
130 King Street West, Suite 900
Toronto, ON M5X 1B1
Canada
Telephone number:
416-699-7222
Fax number:
416-694-0487
Parent Company Information
- Eli Lilly & Company
-
Lilly Corporate Center
Indianapolis, IN 46225
United States of America
Subsidiary Beneficiary Information
Eli Lilly Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Kenneth L Custer,
President and General Manager |
No public offices held
- Jill Daley,
General Counsel & Vice-President Corporate Affairs |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
